YKL-40.com is the leading resource for comprehensive information about YKL-40, a biomarker with potential application in early diagnosis of cancer. YKL-40 has shown promise in research studies as an early diagnostic and prognostic biomarker for ovarian, colorectal and other cancers as well as rheumatoid arthritis and similar debilitating diseases.
"Serum YKL-40 is a promising new cancer marker, one with the potential to detect cancer early in patients with the most aggressive forms of a broad spectrum of cancer types. These are precisely the patients most likely to benefit from initiating cancer treatment early."
- Paul Price USCD

Quidel's Specialty Products Group is focused on delivering innovative research and diagnostic tools with potential downstream POC applications in bone health, oncology and related disease states.

For more information visit www.quidel.com